



DISCLAIMER: The subject of this photo is a model

Alcohol-related brain injury



ADDICTION MEDICINE

Brain changes due to alcohol misuse are often misdiagnosed or not recognised.

RINALDO MINNITI

THE behavioural manifestations of alcohol and other drug use are well known, especially in the context of intoxication. However, the ‘hidden’, long-term effects are less well known.

Brain changes due to regular prolonged alcohol use at harmful levels are often misdiagnosed or not recognised by the general population and even, to a significant degree, by health professionals.

Alcohol-related brain damage has been estimated to occur in 10% of the alcohol-drinking adult population.

Biochemical and morphological changes in the brain due to prolonged alcohol and other drug use

will impact a person’s day-to-day life, even if only at a subtle level.

How drugs act on the brain

The pleasure centre

All drugs that affect mood act on a part of the brain termed the “pleasure centre” by Olds and Milner in 1954. They observed that rats would forgo food, liquid, sleep and sex in order to keep pressing a lever that stimulated a particular area of the brain, which was later found to correlate with the part of the brain that is stimulated by alcohol and other drug use in humans.

The release of dopamine in the pleasure centre produces the mood changes. Virtually all drugs that are misused either directly or

indirectly augment dopamine. Prolonged drug use causes chronic dopamine depletion, which manifests as depressed mood, cravings, lethargy, anhedonia and an amotivational syndrome.

Continued drug use, even when physiological tolerance has developed, is the person’s attempt at trying to feel ‘normal’. In other words, the person feels the need to take the substance to maintain the normal level

Alcohol-related brain damage has been estimated to occur in 10% of the alcohol-drinking adult population.

of dopamine, rather than just wanting the mood altering effects they experienced when they first took the drug.

This phenomenon, along with wanting to avoid the physical withdrawal symptoms is a common motivation for continued drug use.

The depressed mood, anhedonia and amotivational syndrome are not often responsive to psychotropic medications, such as

antidepressants, and efforts to induce enjoyment by ‘getting a hobby’ or interest that afforded them pleasure in the past can also be in vain. Discussion of ‘stimulating’ or meaningful activities is usually more productive.

Long-term effects of alcohol on the brain

Evidence over the past 40 years has shown that significant brain injury occurs with regular prolonged use of alcohol at harmful levels (more than 80g daily).

If a person is over 40 and has at least two of the following characteristics, there is a high probability that they will have alcohol-related brain changes that will impact cognition and day-to-day functioning:

- A history of drinking alco-

hol at harmful levels for the previous 10 years

- Poor nutrition
- A history of regular binge drinking
- Previous participation in medically assisted detoxification programs
- One or more episodes of Werneke’s encephalopathy.


The manifestations of alcohol-related brain injury range from a subclinical syndrome to Korsakoff’s syndrome.

Signs that may indicate alcohol-related brain injury include:

- Deterioration in day-to-day organisational abilities
- Deterioration in problem-solving skills and goal setting

cont’d next page

DISCLAIMER: The subject of this photo is a model



from previous page

- Increase in 'concrete thinking' — the person's thinking style/processes become more rigid
- Reduced ability to manage change with a greater reliance on routine
- Reduced insight into their own behaviour and its impact on others
- Reduced learning capacity such as an inability to learn new instructions/procedures in the workplace.

The cognitive deficits become more apparent in

new environments and can be masked by continuing routines or usual behaviours.

These abilities are generally referred to as executive functions and usually relate to frontal lobe function.

The affected individual may also experience short-term memory problems. However, the attention span is usually within normal limits. The patient may confuse blackouts related to alcohol binges with short-term memory problems, so it is important to distinguish

between the two. Blackouts are related more to the rate of drinking rather than the amount consumed.

Visual-spatial and perceptual-motor abilities may also be impaired. This can manifest as problems in performing tasks that require eye-hand co-ordination. Reaction time may also be impaired.

People with significant alcohol-related brain injury may also:

- Invent stories in order to compensate for memory loss
- Confuse dates of significant events
- Display a lack of insight or acceptance of a link between their symptoms and their alcohol use
- Demonstrate a malleable reactivity in conversations
- Appear to have minimal empathy
- Prefer to live a very restricted lifestyle in a restricted environment.

People with alcohol-related brain injury may have slower reaction times ... and can get disoriented and panic more easily.

Well-learned behaviour patterns such as driving a car can remain intact. However, people with alcohol-related brain injury may have slower reaction times, have difficulty following traffic movements, and can get disoriented and panic more easily. Literary skills are not usually affected to any significant degree.

Imaging

While imaging (MRI or CT) is not required for a diagnosis of alcohol-related brain injury, and there is no evidence of a correlation between the imaging findings and the severity/nature of the injury, the following findings support the presence of the condition:

- Generalised cerebral atrophy
- Widening of the cortical sulci, in particular the Sylvian fissure
- Enlargement of the ventricles, in particular the third ventricle
- Demyelination of the corpus callosum (Macchiafava-Bignami disease).

cont'd page 31



AUSTRALIA'S TOP CHOICE#

For first-line treatment of iron deficiency¹

Ferro-Grad C is Australia's No.1 GP-recommended iron supplement² – the only one with added Vitamin C to aid absorption.^{*1,3} Recommend daily for 3-6 months.^{1,4}

#Based on IMS Sales Data, February 2016. *Of the commercially available forms of iron therapy suitable for the treatment of iron deficiency anaemia. Ferro-Grad C contains dried ferrous sulphate 325 mg (equivalent to 105 mg elemental iron) and sodium ascorbate 562.4 mg (equivalent to 500 mg Vitamin C). For the prevention and treatment of iron deficiency.

References: 1. Iron Deficiency [revised March 2016]. In: eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; March 2016. Accessed May 2016. 2. National Prescribing Service (NPS). Case study 66 report: Iron-deficiency anaemia. January 2011. 3. Brise H & Hallberg L. *Acta Med Scand* 1962;171(Suppl 376):51–8. 4. Pasricha SS *et al. Med J Aust* 2010;193:525–32.

BGP Products Pty Ltd., trading as Mylan EPD. ABN 29 601 608 771. Ph: 1800 314 527. Ferro-Grad C is a registered trademark. AU-FERR-2016-4 May 2016. ABB3265.



from page 28

Wernicke's encephalopathy is a neurological condition associated with significant thiamine deficiency. It is often paired with Korsakoff's syndrome on the basis that if the former remains untreated, it can lead to the latter. However, they are two distinct conditions.

Signs of Wernicke's encephalopathy include:

- Disorientation with confusion of time and place
- Oculomotor disturbances — ophthalmoplegia, nystagmus
- Ataxia marked by wide-based gait (was known as 'sailor's walk'). Cerebellar atrophy, which also causes a wide-based gait, is a differential diagnosis.

The presence of one or more of the above suggests Wernicke's encephalopathy in the context of significant alcohol use and poor nutrition.

Thiamine is the recommended treatment for Wernicke's encephalopathy.

Managing alcohol-related brain injury in general practice

Suspicion of alcohol-related brain injury should be followed by formal psychometric assessment, and comprehensive biographical and alcohol-use history.

Alcohol-related brain injury can occur in people with other mental health issues, such as mood disorder, congenital or acquired/traumatic brain injury and dementia.

Discussions with family members and significant others may be helpful in



DISCLAIMER: The subject of this photo is a model

clarifying the clinical presentation.

Physical examination and blood tests can help identify signs of prolonged alcohol use in other areas of the body, in particular the liver.

Neurological examination can also be useful. However, alcohol-related neurological signs may not be present, even in the presence of significant alcohol use disorder.

Once identified, a patient with alcohol-related brain injury needs to be made aware of the condition, the impact it is having on their thinking, the effect their ongoing alcohol use will have on the brain, and in particular, the reversibility

Recovery of cognitive deficits is possible in many cases and occurs mainly in the first 6-8 weeks.

of their current symptoms. This needs to be conducted in a calm, supportive manner.

The patient should be encouraged to cease alcohol, if not forever, at least for the foreseeable future. This may require the involvement of psychological and support services, as well as the

patient's family and friends.

The psychologist can also discuss such topics as memory retraining strategies, sleep hygiene, and motivation enhancement strategies regarding maintaining abstinence and lifestyle change.

Nutritional deficits should be addressed; in par-

ticular, thiamine should be prescribed.

The GP can, with the support of the psychologist, advocate for the patient at their workplace, if appropriate. The possibility of guardianship and power of attorney may also need to be considered given the results of cognitive assessment.

Follow-up

Ideally, patients with alcohol-related brain injury should be monitored at least monthly for a year after first presentation and initial detoxification. They should also be encouraged to continue ongoing psychotherapy as long-term use

of alcohol at harmful levels can induce a protracted depression.

The patient may also experience symptoms of a generalised anxiety disorder and/or social phobia, as well as sleep problems, which may respond to antidepressant medications (for example, mirtazapine).

Recovery of cognitive deficits is possible in many cases and occurs mainly in the first 6-8 weeks. Given continued abstinence, daily thiamine, multivitamins and good nutrition, improvement can still occur up to a year later.

The support of significant others should be used and support groups, such as Alcoholics Anonymous, can be of great value.

Regular blood tests can be used to monitor recovery and provide incentive for continued abstinence. ●

Mr Minniti is a clinical psychologist with a special interest in addiction medicine, based in Adelaide, SA.

This article is one in a series on brain injuries, commissioned in association with Brain Injury Australia. www.braininjuryaustralia.org.au

References

1. WHO. Neuroscience of psychoactive substance use and dependence. 2004; online. See: bit.ly/2aIRoRF
2. Fals-Stewart W, et al. Neurobehavioural consequences of alcohol and substance abuse: A review of the findings and treatment implications. *Clinical Psychology Review* 1994; 14:755-78.

BREO ELLIPTA
fluticasone furoate/vilanterol



Breo® Ellipta® is indicated for the regular treatment of moderate to severe asthma in patients (≥12 years of age) who require a medium to high dose ICS with a LABA.†



For further information regarding Breo® Ellipta®, including full device use instructions, please refer to the Product Information and visit www.breoellipta.com.au.

ICS = inhaled corticosteroid; LABA = long acting β_2 -agonist. Reference: 1. Breo Ellipta Product Information.

PBS Information – Restricted Benefit: Asthma Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be 12 years or older.
Note: This product is only indicated and PBS reimbursed for maintenance therapy.

PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING. The Product Information can be accessed at http://au.gsk.com/media/266962/breo-ellipta_pi_005_approved.pdf

Breo® Ellipta® (fluticasone furoate/vilanterol trifenate) Minimum Product Information. Indications: Asthma: Regular treatment of moderate to severe asthma in patients requiring medium to high dose inhaled corticosteroid (ICS) combined with long acting β_2 -agonist (LABAs). Chronic Obstructive Pulmonary Disease (COPD): symptomatic treatment of patients with COPD with a FEV₁<70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy. Breo Ellipta is not indicated for the initiation of bronchodilator therapy in COPD. **Contraindications:** Severe milk-protein allergy or hypersensitivity to any of the actives and any excipients. **Precautions:** Long acting β_2 -agonists (LABAs) as a class can be associated with an increased risk of asthma death. Patients using Breo Ellipta should not use another medicine containing a LABA (e.g., salmeterol, eformoterol, indacaterol) for any reason. Cannot be used to relieve acute symptoms of asthma or COPD (short acting β_2 -agonists should be used for acute attacks). As with other inhalation therapy, the possible occurrence of paradoxical bronchospasm immediately after dosing should be treated with short acting β_2 -agonists. As with sympathomimetic drugs, Breo Ellipta should be used with caution in patients with cardiovascular disease. As with all sympathomimetic amines, Breo Ellipta should be used with caution in patients with convulsive disorders or hyperthyroidism. To minimise adverse reactions, ICS should be used at the lowest dose that maintains symptom control. ICS should be used with caution in patients with active or quiescent tuberculosis infections of the respiratory tract; systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. An increase in pneumonia has been observed in patients with COPD. Beta-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. Beta-agonist agents may produce transient hyperglycaemia in some patients. Other: fertility, pregnancy (category B3), lactation. **Interactions:** Beta-blockers, P-glycoprotein inhibitors, CYP3A4 inhibitors, sympathomimetic medicinal products, monoamine oxidase inhibitors, tricyclic antidepressants. **Adverse Reactions:** Very common: headache, nasopharyngitis. Common: URTI, bronchitis, influenza, oral candidiasis of mouth and throat, oropharyngeal pain, sinusitis, pharyngitis, rhinitis, cough, dysphonia, abdominal pain, arthralgia, back pain, pyrexia, muscle spasms. Fractures and pneumonia in patients with COPD. **Dosage:** Prescribers should be aware that 100 mcg of fluticasone furoate is a medium dose of ICS and 200 mcg of fluticasone furoate is a high dose of ICS. Asthma: (Adults and Adolescents ≥ 12 years): 1 inhalation once daily (100/25 mcg or 200/25 mcg). In patients whose asthma is well controlled and stable the Breo Ellipta dose may carefully be down-titrated to the lowest strength of Breo Ellipta. The next step should consider the cessation of Breo Ellipta and transfer to an appropriate inhaled corticosteroid containing regimen. COPD: 1 inhalation once daily (100/25 mcg only). Breo Ellipta 200/25 mcg is not indicated for patients with COPD. Specific patient population: Elderly patients: due to limited data in patients with asthma aged 75 years and older, Breo Ellipta 200/25 mcg is not recommended. Moderate to Severe Hepatic Impairment: once daily maximum dose of 100/25 mcg. Min PI v3.0.

For full product information please contact GlaxoSmithKline Australia Pty Ltd. PO Box 18095, Melbourne, VIC 8003. ABN 47 100 162 481.

For information regarding a GSK product or to report an adverse event, please contact Medical Information on 1800 033 109.

Breo® and Ellipta® are registered trade marks of the GSK group of companies Breo® Ellipta® was developed in collaboration with Theravance.

AUS/FFT/0030/16f Date of Approval: July 2016 S&H GSKBR0079-AD-PA



Theravance